Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419389 · ClinicalTrials.gov registry record · Phase 1
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
A Phase 1 study, sponsored by Aprea Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04419389 is a Phase 1 study that was terminated before completion, run by Aprea Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT04419389, a Phase 1 study, was terminated before completion, sponsored by Aprea Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.
Interventions
- DRUG APR-246 (eprenetapopt) + Acalabrutinib in CLL
- DRUG APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL
- DRUG APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
- DRUG APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2021-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419389
The ClinicalTrials.gov registry entry for NCT04419389 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aprea Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which APR-246 (eprenetapopt) + Acalabrutinib in CLL is the first listed.
NCT04419389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04419389 about?
NCT04419389 is a clinical study titled "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)". Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.
What is the current status of trial NCT04419389?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2021-03-02. Estimated completion is 2021-08-24.
What interventions are being tested in trial NCT04419389?
The interventions under investigation include: APR-246 (eprenetapopt) + Acalabrutinib in CLL (DRUG), APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL (DRUG), APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT (DRUG), APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT (DRUG).
Who is sponsoring clinical trial NCT04419389?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.